{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T20:04:19Z","timestamp":1763755459108,"version":"3.45.0"},"reference-count":11,"publisher":"Oncology Nursing Society (ONS)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CJON"],"published-print":{"date-parts":[[2015,8,1]]},"DOI":"10.1188\/15.cjon.430-432","type":"journal-article","created":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T12:53:30Z","timestamp":1441112010000},"page":"430-432","source":"Crossref","is-referenced-by-count":6,"title":["Nivolumab: Immunotherapy in Malignant Melanoma"],"prefix":"10.1188","volume":"19","author":[{"given":"Heather","family":"Bayless","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1302","published-online":{"date-parts":[[2015,8,1]]},"reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"Ascierto, P.A., Kalos, M., Schaer, D.A., Callahan, M.K., & Wolchok, J.D. (2013). Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types. Clinical Cancer Research, 19, 1009\u20131020.","DOI":"10.1158\/1078-0432.CCR-12-2982"},{"key":"2","unstructured":"Bristol-Myers Squibb. (2013). Yervoy\u00ae (ipilimumab) [Package insert]. Retrieved from http:\/\/packageinserts.bms.com\/pi\/pi_yervoy.pdf"},{"key":"3","unstructured":"Bristol-Myers Squibb. (2015). Opdivo\u00ae (nivolumab) [Package insert]. Retrieved from http:\/\/packageinserts.bms.com\/pi\/pi_opdivo.pdf"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Lipson, E.J. (2013). Re-orienting the immune system: Durable tumor regression and successful re-induction therapy using anti-PD1 antibodies. Oncoimmunology, 2, e23661.","DOI":"10.4161\/onci.23661"},{"key":"5","doi-asserted-by":"crossref","unstructured":"McDermott, D.F., & Atkins, M.B. (2013). PD-1 as a potential target in cancer therapy. Cancer Medicine, 2, 662\u2013673.","DOI":"10.1002\/cam4.106"},{"key":"6","doi-asserted-by":"crossref","unstructured":"Menzies, A.M., & Long, G.V. (2013). New combinations and immunotherapies for melanoma: Latest evidence and clinical utility. Therapeutic Advances in Medical Oncology, 5, 278\u2013285.","DOI":"10.1177\/1758834013499637"},{"key":"7","doi-asserted-by":"crossref","unstructured":"Merelli, B., Massi, D., Cattaneo, L., & Mandal\u00e0, M. (2014). Targeting the PD1\/PD-L1 axis in melanoma: Biological rationale, clinical challenges and opportunities. Critical Reviews in Oncology\/Hematology, 89, 140\u2013165.","DOI":"10.1016\/j.critrevonc.2013.08.002"},{"key":"8","unstructured":"Moffitt Cancer Center. (2015, May 28). Nivolumab treatment in melanoma has manageable safety profile. ScienceDaily. Retrieved from http:\/\/www.sciencedaily.com\/releases\/2015\/05\/150528153517.htm"},{"key":"9","unstructured":"Sullivan, R.J., Lorusso, P.M., & Flaherty, K.T. (2013). The intersection of immune-directed and molecularly targeted therapy in advanced melanoma: Where we have been, are, and will be. Clinical Cancer Research, 19, 5283\u20135291. doi:10.1158\/1078 -0432.CCR-13-2151"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Topalian, S.L., Sznol, M., McDermott, D.F., Kluger, H.M., Carvajal, R.D., Sharfman, W.H., . . . Hodi, F.S. (2014). Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. Journal of Clinical Oncology, 32, 1020\u20131030.","DOI":"10.1200\/JCO.2013.53.0105"},{"key":"11","doi-asserted-by":"crossref","unstructured":"Torino, F., Barnabei, A., Paragliola, R.M., Marchetti, P., Salvatori, R., & Corsello, S.M. (2013). Endocrine side-effects of anti-cancer drugs: mAbs and pituitary dysfunction: Clinical evidence and pathogenic hypotheses. European Journal of Endocrinology, 169, R153\u2013R164.","DOI":"10.1530\/EJE-13-0434"}],"container-title":["Clinical Journal of Oncology Nursing"],"original-title":[],"link":[{"URL":"http:\/\/cjon.ons.org\/cjon\/19\/4\/nivolumab-immunotherapy-malignant-melanoma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:53:12Z","timestamp":1763754792000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ons.org\/publications-research\/cjon\/19\/4\/nivolumab-immunotherapy-malignant-melanoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,1]]},"references-count":11,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,8,1]]}},"URL":"https:\/\/doi.org\/10.1188\/15.cjon.430-432","relation":{},"ISSN":["1092-1095","1538-067X"],"issn-type":[{"type":"print","value":"1092-1095"},{"type":"electronic","value":"1538-067X"}],"subject":[],"published":{"date-parts":[[2015,8,1]]}}}